Athersys to Present at Regen Med Investor Day 2013 in New York 22 hours 16 minutes ago - GlobeNewswire via Comtex Athersys, Inc. (Nasdaq:ATHX) announced today that Chairman and CEO, Gil Van Bokkelen, will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City.
Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Burrill & Company, Maxim Group and Piper Jaffray, this flagship event features sixteen of the regenerative medicine field's leading small- and mid-cap companies. In addition, there will be disease indication focused discussions between key opinion leaders, top analysts and senior executives from the sector and keynote style talks by Jeff Jonas, President of Shire Regenerative Medicine, and Kieran Murphy, President and CEO, GE Healthcare Life Sciences.
The following are specific details regarding Athersys' presentation at the conference:
Event: ARM's Regen Med Investor Day Date: April 17, 2013 Time: 1:15 p.m. EDT Location: Harmonie Club, 4 East 60th Street, New York, NY 10022 A live video webcast of the company presentations will be available at: http://alliancerm.org/rmdaywebcast and will also be published on ARM's website shortly after the event.
In addition to the corporate presentation, Dr. Van Bokkelen will also participate in a panel that will discuss how advanced approaches in regenerative medicine are being developed to address significant unmet medical needs in the neurological area. Athersys is focused on the development of MultiStem to treat acute and chronic neurological conditions, including stroke, traumatic brain injury, multiple sclerosis and spinal cord injury, as well as other programs.
Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending please contact Laura Parsons at email@example.com. Please visit http://alliancerm.org/event/regen-med-investor-day for more information.
Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including treatment of inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft versus host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.